SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
SEELAS Life Sciences (US:SLS) Globenewswire·2026-11-13 05:05- Topline Primary Endpoint Results of the Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia Following the 80th Event to Report this Month - - 40 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Preliminary Topline Data Expected in Q4 2026 - - $134.7 Million in Cash and Cash Equivalents as of September 30, 2026 - NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biop ...